Guidelines recommend diuretics, angiotensin IIreceptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs), andmineralocorticoid receptor antagonists (MRAs) for HF patients, but these drugtreatments may contribute to dyskalemia [3, 4, 5]. This evidence concerns the gene ACE and hydrops fetalis.